Girindus AG - Oligonucleotide Production Expansion Accelerated

Bensberg (OTS) - Girindus, with core competencies in process development, scale up and manufacture of innovative drug and cosmetic actives, sees a significant increase in demand for its commercial oligonucleotide production capabilities in the USA and Europe.

"Our know-how and our technical expertise in the area of oligonucleotide research, development and manufacturing has been validated by an increased market demand. To respond to this demand we have accelerated the expansion program of our US commercial cGMP manufacturing facility located in Cincinnati Ohio", commented the CEO Robert F. Link.

In addition to the solid phase production in Cincinnati Girindus offers a unique solution phase process at its European facility which is targeted towards the cost-efficient manufacture of large commercial quantities.

Originaltext: Girindus AG digital press kits: http://presseportal.de/story.htx?firmaid=23521 press kits via RSS: feed://presseportal.de/rss/pm_23521.rss2 ISIN: DE0005880405

For further information, please contact:

Rückfragen & Kontakt:

Peter J. Bergsteiner,
Director Investor Relations
Girindus AG, 51402 Bensberg
T: +49 - (0)2204 - 926 - 900
F: +49 - (0)2204 - 926 - 990
pbergsteiner@girindus.com

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | EUN0010